These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Genetics of pancreatic neuroendocrine tumors: implications for the clinic. Pea A; Hruban RH; Wood LD Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978 [TBL] [Abstract][Full Text] [Related]
8. Genetics and prevention of pancreatic cancer. Vimalachandran D; Ghaneh P; Costello E; Neoptolemos JP Cancer Control; 2004; 11(1):6-14. PubMed ID: 14749618 [TBL] [Abstract][Full Text] [Related]
9. Screening for pancreatic cancer in high-risk individuals: a call for endoscopic ultrasound. Larghi A; Verna EC; Lecca PG; Costamagna G Clin Cancer Res; 2009 Mar; 15(6):1907-14. PubMed ID: 19276278 [TBL] [Abstract][Full Text] [Related]
10. Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges. Jiang Z; Zheng X; Li M; Liu M Front Med; 2023 Dec; 17(6):1135-1169. PubMed ID: 38151666 [TBL] [Abstract][Full Text] [Related]
11. Hereditary Pancreatic Cancer Syndromes: Providing Care to At-Risk Families. King E; Nehoray BM Clin J Oncol Nurs; 2019 Dec; 23(6):579-582. PubMed ID: 31730603 [TBL] [Abstract][Full Text] [Related]
12. Genetics of Pancreatic Cancer and Its Implications on Therapy. Tatarian T; Winter JM Surg Clin North Am; 2016 Dec; 96(6):1207-1221. PubMed ID: 27865273 [TBL] [Abstract][Full Text] [Related]
14. Inherited pancreatic cancer: improvements in our understanding of genetics and screening. Rulyak SJ; Brentnall TA Int J Biochem Cell Biol; 2004 Aug; 36(8):1386-92. PubMed ID: 15147717 [TBL] [Abstract][Full Text] [Related]
15. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds. Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920 [TBL] [Abstract][Full Text] [Related]
16. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222 [TBL] [Abstract][Full Text] [Related]
17. DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development. Golan T; Javle M J Natl Compr Canc Netw; 2017 Aug; 15(8):1063-1069. PubMed ID: 28784866 [TBL] [Abstract][Full Text] [Related]
18. The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. Martinez-Useros J; Garcia-Foncillas J Biomed Res Int; 2016; 2016():1869304. PubMed ID: 28078281 [TBL] [Abstract][Full Text] [Related]
19. Molecular technology and pancreatic cancer. Manu M; Buckels J; Bramhall S Br J Surg; 2000 Jul; 87(7):840-53. PubMed ID: 10931017 [TBL] [Abstract][Full Text] [Related]
20. Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. Chu D; Kohlmann W; Adler DG JOP; 2010 May; 11(3):203-12. PubMed ID: 20442513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]